From applesvtoe33@krashtan.kiev.ua  Fri Jan 10 14:27:57 2003
Return-Path: <applesvtoe33@krashtan.kiev.ua>
Received: from mx1.FreeBSD.org (mx1.freebsd.org [216.136.204.125])
	by hub.freebsd.org (Postfix) with ESMTP id 03D0B37B401
	for <freebsd-gnats-submit@freebsd.org>; Fri, 10 Jan 2003 14:27:57 -0800 (PST)
Received: from in-clab-with.ads.iu.edu (with.iupui.edu [134.68.158.15])
	by mx1.FreeBSD.org (Postfix) with ESMTP id 4A55D43F5B
	for <freebsd-gnats-submit@freebsd.org>; Fri, 10 Jan 2003 14:27:52 -0800 (PST)
	(envelope-from applesvtoe33@krashtan.kiev.ua)
Received: from mail.baysystems.com.pk ([24.209.65.245]) by in-clab-with.ads.iu.edu with Microsoft SMTPSVC(5.0.2195.5329);
	 Fri, 10 Jan 2003 17:27:50 -0500
Message-Id: <000007592fce$00002787$00006f9d@mail.planet.net.hk>
Date: Fri, 10 Jan 2003 14:27:33 -2000
From: "Diana" <applesvtoe33@krashtan.kiev.ua>
To: <newjr1999@hotmail.com>
Cc: <dandrewl@hotmail.com>, <ekralick@access1.net>,
	<craigcuth@sncorp.com>, <kodiak@kvi.fanz.net>,
	<freebsd-gnats-submit@freebsd.org>, <wjung@access.digex.net>,
	<crashamb@aol.com>, <andy@wolfsong.com>, <gypsy_and_barb@yahoo.com>,
	<catoleeo@comteck.com>, <dave@teamadventures.com>
Subject: Press Release Upcoming OTC BB Market Moving Stock Picks21636

>Number:         46962
>Category:       junk
>Synopsis:       Press Release Upcoming OTC BB Market Moving Stock Picks21636
>Confidential:   no
>Severity:       serious
>Priority:       medium
>Responsible:    gnats-admin
>State:          closed
>Quarter:        
>Keywords:       
>Date-Required:  
>Class:          sw-bug
>Submitter-Id:   current-users
>Arrival-Date:   Fri Jan 10 14:30:02 PST 2003
>Closed-Date:    Mon Jan 13 11:37:14 PST 2003
>Last-Modified:  Wed Oct 06 19:59:42 GMT 2004
>Originator:     
>Release:        
>Organization:
>Environment:
>Description:
 BioCurex PRESS RELEASE
 Source: BioCurex, Inc.
 
 January 9, 2003
 
 OTCBB Listed BioTech Companies BOCX & RJVN - 
 Creating a Non-Toxic Therapeutic Antibody Cancer
 Treatment That May Arrest Development and Replication
 of Cancerous Cells.
 
 Rancho Santa Margarita, Calif., January 9, 2003 BioCurex, 
 Inc., (OTC BB:BOCX), Announces further developments 
 relating to its licensing agreement with BioKinetix,
 a company being acquired by RJV Networks, Inc., 
 (OTC BB : RJVN).
 
 BioCurex and RJV networks (through Biokinetix) are
 behind the development of a new therapeutic product,
 which experts believe will arrest the development of
 and replication of cancerous cells that cause the
 growth of malignant tumors.
 
 BOCX's proprietary technology has identified a New 
 Widespread Cancer marker Molecule named RECAF.
 Cancer "markers" are molecules that appear on cancer 
 cells but not on normal cells and have been hailed as
 The Holy Grail of cancer research since they can be 
 used to detect (diagnose) and then specifically target 
 cancer cells (therapy) - offering the potential to
 provide treatment of cancer by delivering antibodies
 to the targeted cancerous cells.
 
 RJVN and BioKinetics have proprietary technology for
 developing "superantibodies", an enhancement of antibody
 technology that makes ordinary antibodies much more lethal.
 The combination of anti-RECAF antibodies from BioCurex with
 the superantibody technology from RJVN - BioKinetics is
 expected to produce a powerful therapeutic agent to combat
 most types of cancer.
 
 If the antibodies prove to be cancer cell specific, it
 is unlikely that there would be any adverse side effects.
 This lack of toxicity should accelerate testing and
 approval process.
 
 Dr. Moro, President of Biocurex stated: "Our ultimate
 goal is to fight cancer. We have the cancer marker that
 identifies the cancer cells and RJV Networks-BioKinetix
 has the superantibody technology to kill them. It is only
 natural that we join forces in the battle against this
 horrible disease. I see tremendous potential for success
 in this joint effort.
 
 Dr. John Todd, President of BioKinetix Corporation stated
 that Bio Kinetix Corporation's mission is to acquire
 intellectual property rights for existing products
 and intellectual property. Then, through a series of
 collaborative relationships, we will facilitate the
 development of a new generation of monoclonal antibodies
 (termed "Superantibodies), which will have a significantly
 improved therapeutic potency as anticancer agents.
 
 BioCurex, Inc.
 Richard Moro, President
 
 RJV Networks-BioKinetix
 Grant Young
 
 
 For more info see RJVN  and BOCX in the news.
 You can also see this Press Release at Yahoo Finance
 biz.yahoo.com/pz/030109/35412.html
 You can also look them up by their symbols: 
 OTC BB:BOCX or OTC BB : RJVN
  
 
 
 **** Special Financial-Stock Opt-in mailing list Offer ****
 As a member of our special opt-in mailing list, you will
 be among the first to receive up to the minute information
 regarding the companies we profile above as well as a
 free 10-day trial to a website with real-time Level II quotes,
 research reports, OTC BB promo / syndication calendar,
 trading chat rooms, full threading message boards, along
 with many other valuable and free investment tools not
 readily available to the general public. This is an
 incredible opportunity! Just click the link below to
 send us an email, and you will be immediately added to
 our Opt-in list. Please be sure that "opt-in" is in the
 subject line of the email. If opt-in is not in the subject line
 you will not be added. 
 MailTo:uhl669@excite.com?Subject=Opt-In 
 Thank you.
 
 **See Removal instructions below
 
 
 ***********************Disclaimer********************
 Information within this email contains "forward looking
 statements" within the meaning of Section 27A of the
 Securities Act of 1933 and Section 21B of the Securities
 Exchange Act of 1934. Any statements that express or
 involve discussions with respect to predictions, goals,
 expectations, beliefs, plans, projections, objectives,
 assumptions or future events or performance are not
 statements of historical fact and may be "forward
 looking statements."
 
 Forward looking statements are based on expectations,
 estimates and projections at the time the statements
 are made that involve a number of risks and uncertainties
 which could cause actual results or events to differ
 materially from those presently anticipated. Forward
 looking statements in this action may be identified
 through the use of words such as: "projects", "foresee",
 "expects", "estimates," "believes," "understands" "will,"
 "anticipates," or that by statements indicating certain
 actions "may," "could," or "might" occur. All information
 provided within this email pertaining to investing, stocks,
 securities must be understood as information provided and
 not investment advice. Emerging Equity Alert advises all
 readers and subscribers to seek advice from a registered
 professional securities representative before deciding to
 trade in stocks featured within this email. None of the
 material within this report shall be construed as any
 kind of investment advice.
 
 In compliance with the Securities Act of 1933,
 Section 17(b), Emerging Stock Alert discloses the
 receipt of 125,000 unrestricted shares of RJVN from
 a third party for the publication of this report. Be
 aware of an inherent conflict of interest resulting
 from such compensation due to our intent to profit
 from the liquidation of these shares. Shares may be
 sold at any time, even after positive statements have
 been made regarding the above company. All factual
 information in this report was gathered from public
 sources, including but not limited to SEC filings,
 Company Press Releases, and Market Guide. Emerging
 Equity Alert believes this information to be reliable
 but can make no guarantee as to its accuracy or
 completeness. Use of the material within this email
 constitutes your acceptance of these terms.
 
 
 ****** Advertising Disclaimer ******
 
 We are an Internet Advertising Company and have received
 a monetary payment for this mailing service. We hold no
 stocks and have no personal interest in this company
 whatsoever. We are simply being paid to perform a service.
 This message is a copy of a BioCurex press release.
 
 
 ****** Removal Instructions ******
 This message has been sent to you in compliance with
 our strict anti-abuse regulations. We will continue to
 bring you valuable offers on the products and services
 that interest you most. If you do not wish to receive
 further mailings, please click below. We respect all
 removal requests. To be removed immediately from our
 mailing lists just click on the link below:
 MailTo:billt4681@excite.com?Subject=expunge . 
 Be sure that "purge-me" is in the subject line
 of the email prior to sending it.
 
 
 
 
 
 ****************************************************************
 ***************************
 
>How-To-Repeat:
>Fix:
>Release-Note:
>Audit-Trail:
State-Changed-From-To: open->closed 
State-Changed-By: ceri 
State-Changed-When: Mon Jan 13 11:36:51 PST 2003 
State-Changed-Why:  
Spam. 

http://www.freebsd.org/cgi/query-pr.cgi?pr=46962 
>Unformatted:
